Biotech News

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.2026-07-03 01:30 ESTCompany update

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares,

Open original release

Related news

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

View all latest news

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

MISTZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

MISTZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

MISTBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

MISTGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

MISTMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 1.28 USD
Market cap: 159.36M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States